]. In the TACTIC trial, NT-proBNP was lower in the TA-65 group after 12 months , but the treatment effect was not statistically significant.
The major limitation of canakinumab in the CANTOS trial was the effect of IL-1β blockade on immunity. Patients in the treatment group had more infections, and a higher risk of dying from sepsis. However, our data shows that patients treated with TA-65 have no significant change in myeloid cells compared to placebo, suggesting they do not have impaired innate immunity. Indeed, their adaptive immunity appears to be enhanced, as indicated by an increase in the number of all lymphocyte subsets.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: